Kineta vaccine adjuvants improve vaccine protection
These adjuvants may be instrumental in increasing the effectiveness of vaccines, reducing vaccine dosages and boosting cross protection.
Kineta researchers discovered the molecules by using the company’s proprietary AViid discovery platform. This platform uses the small adjuvant molecules to create immune pathways dependent on the IRF. The adjuvant system improved the anti-viral cellular immune response as well as the production of antibodies when it was included with the vaccine in Kineta’s animal models.
Adjuvants are molecules that are supplementary to the vaccine and enhance the body’s response to the immune system.
“Our vaccine adjuvants enhance the protection conferred by existing influenza vaccines as demonstrated in lethal mouse infection models, and are also dose sparing and have the potential to strengthen the effectiveness of a variety of vaccines,” Kineta's associate director of program management and virology Chelsea Olsen said. “In addition, unlike conventional vaccine adjuvants, our host directed small molecule compounds stimulate innate antiviral pathways which results in a more specific response."
Olsen recently presented this information at the World Vaccine Congress.